logo

For the Inventor, By the Inventor

Iruma, Japan

Noboru Maki

This inventor holds 6 USPTO granted patents. Top assignee: Tonen Corporation. Active years: 1994-1998.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Noboru Maki. Retrieved from https://idiyas.com/inventor/noboru-maki-03turbro

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 6

% Patents Active = 100.0

Average Co-Inventor Count = 4.7

ph-index = 3

Forward Citations = 37(Granted Patents)


Location History:

  • Iruma, JP (1994)
  • Saitama, JP (1995)
  • Iruma-gun, JP (1997 - 1998)

Company Filing History:

goldMedal6 out of 141 
 
Tonen Corporation
 patents

Years Active: 1994-1998

Loading Chart...
6 patents (USPTO):Explore Patents
1. 5800982 - Antigenic peptides for growing hepatitis C virus, kit comprising the (1998-09-01),
2. 5759802 - Production of human serum alubumin A (1998-06-02),
3. 5662906 - Non-a non-b hepatitis-specific antigen and its use in hepatitis diagnosis (1997-09-02),
4. 5641654 - Non-A non-B hepatitis specific antigen and its use in hepatitis (1997-06-24),
5. 5416015 - Isolated genes encoding peptidyl prolyl-cis.trans-isomerase and plasmids (1995-05-16),
6. 5284762 - Peptidyl prolyl-cis.trans-isomerase (1994-02-08),

Title: Noboru Maki: Innovator in Hepatitis C Research

Introduction

Noboru Maki is a distinguished inventor based in Iruma-gun, Japan. He has made significant contributions to the field of medical research, particularly in the development of diagnostic tools for hepatitis C virus (HCV). With a total of 6 patents to his name, Maki's work has the potential to impact the diagnosis and treatment of HCV infections.

Latest Patents

Maki's latest patents include innovative solutions for growing hepatitis C virus and improving diagnostic methods. One of his notable inventions is an antigenic peptide that reacts specifically with antibodies directed against Group I and Group II of HCV. This invention also includes a kit designed for identifying HCV Groups I or II, which can aid in the early detection of mixed infections. Additionally, Maki has developed a process for the production of human serum albumin A (HSA), which involves culturing host cells transformed with specific plasmids to produce and secrete mature HSA.

Career Highlights

Maki is currently associated with Tonen Corporation, where he continues to advance his research in the field of virology. His work has garnered attention for its potential applications in improving patient outcomes for those infected with hepatitis C.

Collaborations

Maki has collaborated with notable colleagues, including Kenjiro Yamaguchi and Masanori Suzuki, to further enhance the impact of his research. Their combined expertise has contributed to the development of innovative solutions in the medical field.

Conclusion

Noboru Maki's contributions to hepatitis C research exemplify the importance of innovation in medical science. His patents and ongoing work continue to pave the way for advancements in diagnosis and treatment, ultimately benefiting patients worldwide.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…